Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol vs iron sucrose in pediatric CKD-related iron deficiency anemia
2024-516263-92-00Phase 3Authorised
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Sep 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of ferumoxytol in iron deficiency anemia (IDA) and chronic kidney disease (CKD) (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoints: Proportion of patients achieving hemoglobin increase ≥0.5 g/dL, Proportion of patients achieving hemoglobin increase ≥0.5 g/dL or TSAT increase ≥10% and 14 more. Planned start Sep 2024; status: authorised.
02
Drugs
ferumoxytol
03
Conditions
iron deficiency anemia (IDA)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-516263-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516263-92-00.